PUNE: Emcure Pharmaceuticals, one of India’s leading pharmaceutical companies, unveiled its new corporate campaign with the tagline – ‘Cure and Beyond’, featuring cricketer MS Dhoni.

In the ever-evolving world of healthcare, Emcure Pharmaceuticals is all set to cement its belief in ‘Cure and Beyond’. The campaign not only seeks to raise awareness about innovation as the cornerstone of Emcure’s operations but also aims to cultivate thought leadership within the Indian Pharmaceutical Market.

The campaign is built upon a compelling narrative that transcends the conventional role of offering pharmaceutical products to patients. It delves into a broader mission of supporting, empowering, and educating millions of people to lead healthier lives. The ad film, featuring ‘Captain Cool,’ is being launched across various media platforms, encompassing digital, television, and print.

Speaking on the occasion, Satish Mehta, Managing Director and CEO of Emcure Pharmaceuticals, said, “At Emcure, we have always been striving to move the needle. The campaign ‘Cure and Beyond’ is our endeavor to put forth our vision and what we stand for. And who better to take this forward than a man who has gone above and beyond all through his life- Dhoni. With this effort, we want to reinforce our core belief of empowering people and communities through innovation.”

For Emcure Pharmaceuticals, good health and well-being are just the starting points for a life full of aspirations and achievements.

The video can be watched online on YouTube by clicking on the below link:

The post Emcure Pharmaceuticals Unveils Campaign ‘Cure And Beyond’ Featuring MS Dhoni appeared first on NRI News.

Emcure Pharmaceuticals has been operating manufacturing facilities across 13 sites in India for decades. The company’s manufacturing facilities are capable of producing pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, biotherapeutics, and complex APIs. The company has approvals and accreditations from various regulatory authorities such as EDQM, Health Canada, USFDA, ANVISA Brazil, and more.

The new manufacturing plant in Mehsana will create additional job opportunities in the local market. Speaking on the occasion, Satish Mehta, Founder and CEO, of Emcure Pharmaceuticals, said, “The new Mehsana facility represents our continued investment in Gujarat, aligning with our vision to bring solutions to address the unmet medical needs and improve patient outcomes globally.“

Emcure Pharmaceuticals is proposing an initial public offering of its equity shares subject to receipt of requisite approvals, market conditions, and other considerations. The company has filed a draft red herring prospectus with the Securities and Exchange Board of India.

Emcure Pharmaceuticals Ltd. is one of India’s leading pharmaceutical players headquartered in Pune with a global footprint and is driven by technology and innovation. Established in 1981, the firm was founded by Mr. Satish Mehta and is ranked as the 13th largest pharma company in India in terms of domestic sales.

The post Emcure Pharmaceuticals Expands Manufacturing Footprint in Gujarat, Inaugurates New Injectables Facility appeared first on NRI News.

Dose suitable for the majority of Indian patients with Iron Deficiency and Iron Deficiency Anemia

Will make it more convenient to Treat Iron Deficiency and Iron Deficiency Anemia in India

PUNE: Emcure Pharmaceuticals Limited (EPL) has announced the launch of Orofer FCM 750, a new extension of its parenteral iron brand containing Ferric carboxymaltose (FCM).

The new dosage variant is designed to provide a more effective and convenient option for patients with iron deficiency and iron deficiency anemia (IDA). DCGI-approved FCM is indicated for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. It is already available in dosage forms 1000mg/ 20ml and 500mg/ 10ml single-use vials. With this latest launch, Orofer FCM will also be available as a 750mg/15ml dosage form recommended for the treatment of patients with Hemoglobin less than 10 g/dl & bodyweight between 35 kg to 70kg. Orofer FCM can only be obtained through a prescription from a registered medical practitioner.

IDA is a significant burden for women, especially during later trimesters of pregnancy and secondary to postpartum hemorrhage (PPH). Approximately 36% of maternal deaths are attributed to PPH1 as per Indian studies; whereas anemia during pregnancy is reported among 45.7% and 54.3% of pregnant women in urban and rural areas2, respectively, hampering post-partum maternal and early child health outcomes. Indian studies using FCM for the treatment of IDA in pregnancy have indicated that most patients have mean Haemoglobin <10 g/dl.3,4 They may require FCM 1500 mg at body weight between 35-70 kgs. A single dose of FCM up to 750 mg of iron can be infused in a short time frame of 15 minutes diluted in 250 ml of normal saline5.

Anil Kothiyal, President of India Business at Emcure Pharmaceuticals said “At Emcure Pharmaceuticals, we recognize IDA as a major public health concern in India, particularly among women. We feel satisfied to introduce Orofer FCM 750 to help address this significant burden of IDA in India. This bolsters our commitment to providing innovative and effective solutions to meet the healthcare needs of patients in India. We believe Orofer FCM 750, with its convenient dosage strength, will provide an important treatment option for patients with IDA who may not have responded to oral iron preparations or who cannot tolerate them. Orofer FCM will be available in leading pharmacies and hospitals shortly”

In April 2018, the Intensified National Iron Plus Initiative (I-NIPI) operational guidelines for the “Anemia Mukt Bharat” Programme recommended FCM as the first-line treatment for severe and selected cases of mild-to-moderate anemia in pregnant women in India.6 FCM, a unique iron complex consisting of a ferric hydroxide core stabilized by a carbohydrate shell, enabling controlled iron delivery to target tissues. FCM can elevate serum ferritin and Hemoglobin levels and provide better compliance as compared to oral iron and iron sucrose therapy.

The post Emcure Pharmaceuticals becomes the First Company in India to launch the 750 mg injectable variant of Ferric carboxymaltose appeared first on NRI News.